Neuren Pharmaceuticals (ASX:NEU) is advancing preparations for a phase 3 trial of its drug candidate NNZ-2591 in children with Phelan-McDermid syndrome, according to a Monday filing with the Australian Securities Exchange.
The Phelan-McDermid syndrome is a rare genetic disorder characterized by the loss or structural change in a portion of chromosome 22.
The announcement follows a meeting with the US Food and Drug Administration in which the company and the US FDA reached alignment on key aspects of the program, with the company submitting additional information to confirm endpoints for the primary efficacy assessment
The 13-week program is a single randomized, double-blind, placebo-controlled trial, the filing said.
Shares rose almost 3% in recent Monday trade.
Price (AUD): $14.43, Change: $+0.38, Percent Change: +2.70%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。